Name (Synonyms) | Correlation | |
---|---|---|
drug1053 | High Dose of KBP-COVID-19 Wiki | 1.00 |
drug1822 | Placebo Wiki | 0.06 |
Name (Synonyms) | Correlation | |
---|---|---|
D003141 | Communicable Diseases NIH | 0.09 |
D007239 | Infection NIH | 0.06 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
This is an First In Human (FIH), observer-blinded, randomized, placebo-controlled, parallel group study to evaluate the safety and immunogenicity of KBP-COVID-19 vaccine in healthy CoV-2seronegative adult subjects in 2 age groups, Part A (18-49 years) and Part B (50-70 years).
Description: Occurrence of Adverse Events
Measure: Solicited Administration site reactions Time: 7 days after vaccinationDescription: Occurrence of Adverse Events
Measure: Solicited systemic events Time: 7 days after vaccinationDescription: Safety Endpoints
Measure: Unsolicited Adverse Events and medically attended adverse events Time: 43 days after vaccinationDescription: Safety Endpoints
Measure: Serious Adverse Events, Medically Attended Adverse Events and New Onset Chronic Diseae Time: 365 days after vaccinationDescription: Immunogenicity
Measure: Vaccine ELISA and neutralizing antibody titers for each treatment group Time: Baseline, Day 8, 15, 22, 29, 43, 90, 181, 273, 365Description: Immunogenicity
Measure: Seroconversion rates Time: Days 8, 15, 22, 29, 43, 90, 181, 273, 365